Aluminium overload after 5 years in skin biopsy following post-vaccination with subcutaneous pseudolymphoma

Journal of Trace Elements in Medicine and Biology

Volumn 26, Issue 4, 2012, Pages 291-293

  Guillard, Olivier ^a   Fauconneau, Bernard ^a   Pineau, Alain ^b   Marrauld, Annie ^a   Bellocq, Jean Pierre ^c   Chenard, Marie Pierre ^c  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Aluminium; Pseudolymphoma; Toxicity; Vaccine; Zeeman Electrothermal Atomic Absorption Spectrophotometry (ZEAAS)

Indexed keywords

ALUMINUM HYDROXIDE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; HEPATITIS B VACCINE;

ADULT; ALUMINUM OVERLOAD; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CASE REPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIPHTHERIA; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; INJECTION SITE; MACROPHAGE; POLIOMYELITIS; PRIORITY JOURNAL; PSEUDOLYMPHOMA; SKIN BIOPSY; SUBCUTANEOUS NODULE; SUBCUTANEOUS PSEUDOLYMPHOMA; TETANUS; VACCINATION; ZEEMAN ELECTROTHERMAL ATOMIC ABSORPTION SPECTROPHOTOMETRY;

ALUMINUM; ALUMINUM HYDROXIDE; BIOPSY; FEMALE; HUMANS; MIDDLE AGED; PSEUDOLYMPHOMA; SKIN; SUBCUTANEOUS TISSUE; VACCINATION;

EID: 84868204379     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2012.02.005     Document Type: Article

References (22)

1. Flarend R.E., Hem S.L., Whithe J.L., Elmore D., Suckow M.A., Rudy A.C., et al. In vivo absorption of aluminium containing vaccine adjuvants using 26Al. Vaccine 1997, 15:1314-1318.
2. Exley C., Swarbrick L., Gherardi R.K., Authier F.J. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009, 72:135-139.
3. Exley C., Siesjö P., Ericksson H. The immunobiology of aluminium adjuvants: how do they really work. Trends Immunol 2010, 31:103-109.
4. Gherardi R.K., Coquet M., Cherin P., Belec L., Moretto P., Dreyfus P.A., et al. Macrophagic myofasciitis lesions assess long-term persistent of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
5. Authier F.J., Sauvat S., Champey J., Drogou I., Coquet M., Gherardi R.K. Chronic fatigue syndrome in patient with macrophagic myofasciitis concise communications. Arthritis Rheum 2003, 48:569-572.
6. Couette M., Boisse M.F., Maison P., Brugieres P., Cesaro P., Chevalier X., et al. Long term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem 2009, 103:1571-1578.
7. Cosnes A., Flechet M.L., Revuz J. Inflammatory nodular reactions after hepatitis B vaccination due to aluminium sensitization. Contact Dermatitis 1990, 23:65-67.
8. Hernandez I., Sanmartin O., Carda C., Gomez S., Alfaro A. B-cell pseudolymphoma caused by aluminium hydroxide following hyposensitization therapy. Actas Dermosifiliogr 2008, 99:213-216.
9. Maubec E., Pinquier L., Viguier M., Caux F., Amsler E., Aractingi S., et al. Vaccination induced cutaneous pseudolymphoma. J Am Acad Dermatol 2005, 52:623-629.
10. Pineau A., Guillard O., Chappuis P., Arnaud J., Zawislak R. Sampling conditions for biological fluids for trace element monitoring in hospital patients: a critical approach. Crit Rev Clin Lab Sci 1987, 17:1593-1595.
11. Guillard O., Tiphaneau K., Reiss D., Piriou A. Improved determination of aluminium in serum by electrothermal atomic absorption spectrometry and Zeeman background correction. Anal Lett 1984, 17:1593-1605.
12. Van Gikel M.F., Van der Voet G.B., De Wolff F.A. Improved method of analysis for aluminium in brain tissue. Clin Chem 1990, 36:658-661.
13. Deloncle R., Huguet F., Babin P., Fernandez B., Quellard N., Guillard O. Chronic administration of aluminium l-glutamate in young mature rats: effects on iron levels and lipid peroxidation in selected brain areas. Toxicol Lett 1999, 104:65-73.
14. Weber J.P. An interlaboratory comparison program for several toxic substance in blood and urine. Sci Total Environ 1988, 71:111-123.
15. Guillard O., Pineau A., Baruthio F., Arnaud J. An international quality assessment program for measurement of aluminum in human plasma: a progress report. Clin Chem 1988, 34:1603-1604.
16. Shaw C.P., Petrik M.S. Aluminium hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem 2009, 103:1555-1562.
17. Savory J., Exley C., Forbes W.F., Huang Y., Joshi J.G., Kruck T., et al. Can the controversy of the role of aluminium in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?. J Toxicol Environ Health 1996, 48:615-635.
18. Exley C. Does antiperspirant use increase the risk of aluminium related disease, including Alzheimer's disease?. Mol Med Today 1998, 4:107-109.
19. Guillard O., Fauconneau B., Olichon D., Dedieu G., Deloncle R. Hyperaluminemia in a woman using an aluminium-containing antiperspirant for 4 years. Am J Med 2004, 117:956-959.
20. Darbre P.D. Aluminium, antiperspirants and breast cancer. J Inorg Biochem 2005, 99:1912-1919.
21. McGrath K.G. Apocrine sweat gland obstruction by antiperspirants allowing transdermal absorption of cutaneous generated hormones and pheromones as a link to the observed incidence rates of breast and prostate cancer in the 20th century. Med Hypoth 2009, 72:665-674.
22. Tomljenovic L., Shaw C. Aluminum vaccine adjuvants: are they safe?. Curr Med Chem 2011, 18:2630-2637.